Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.
Target Price
The average target price of CNTX is 5.7 and suggests 156% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell